Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Immunophenotyping of immune infiltrates by flow cytometry
- Last Updated
- 6 years ago
Overview
Brief Summary
Multicentric interventional prospective study with collection of biological samples as part of a routine care research
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age greater than or equal to 18 years.
- •Male and female sex.
- •Any patient with cancer (see list in the body of the protocol) requiring treatment by surgical resection and / or who will start treatment with mAb or BiTE.
- •Patient information and signed informed consent.
- •Subjects affiliated (or beneficiary) to a social security scheme
- •Patients treated for immune complications by immunosuppressants may be included (corticosteroids, etc.).
Exclusion Criteria
- •History of severe systemic autoimmune disease.
- •Pregnant or breastfeeding patient
- •Impossibility or refusal to sign informed consent
- •Patient under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision
Outcomes
Primary Outcomes
Immunophenotyping of immune infiltrates by flow cytometry
Time Frame: Up yo one year
Immunophenotyping analysis by flow cytometry (Cyan, Beckman Coulter): identification of several immune sub-populations (T-B-NK lymphocytes, myeloid and tumor cells); identifications of several receptors and ligands (PD1 / PDL1, Tim-3 / HAVCR2,, CTLA-4, 4-1BB / 4-1BBL, Fas / FasL, TRAIL, OX40 / OX40L, ICOS / ICOSL, CD69, CD25 / CD127, NKp46 / NKp30, NKG2D / NKG2DL, galectin-9, MHC class I and II, B7H3 / B7H6); identification of memory subpopulations (CD45RA / CD27 / CCR7) and, if available, intra-cytoplasmic labeling (CXCR3, CCR6, Granzyme B, KI67, TNFα IFNg, IL-17 and IL-21).